A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

Inclusion Criteria:

• Confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy.
• Adequate coagulation, liver and renal function.
• Candidate for DCE-MRI evaluation.
• ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.

Exclusion Criteria:

• Evidence of bleeding problems.
• Uncontrolled hypertension.
• Certain gastrointestinal problems including fistula and abscess.
• Patients with primary brain cancer.